Section 14. Combination of entecavir plus low-dose on-demand hepatitis b immunoglobulin is effective with very low hepatitis b recurrence after liver transplantation

Transplantation

Volumn 97, Issue 8, 2014, Pages S53-S59

  Hu, Tsung Hui ^a   Chen, Chao Long ^a   Lin, Chih Che ^a   Wang, Chih Chi ^a   Chiu, King Wah ^a   Yong, Chee Chien ^a   Liu, Yueh Wei ^a   Eng, Hock Liew ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Entecavir; Hepatitis B; Lamivudine; Liver transplantation

Indexed keywords

BASILIXIMAB; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; METHYLPREDNISOLONE; NUCLEOSIDE; PREDNISOLONE; TACROLIMUS; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; GUANINE; HEPATITIS B HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

ACUTE HEART INFARCTION; ADULT; AGE; ANTIVIRAL RESISTANCE; ARTICLE; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIOPERATIVE BLEEDING; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; SEPSIS; SEX; STOMACH CANCER; TAIWAN; TRAFFIC ACCIDENT; VASCULAR DISEASE; VIRUS RESISTANCE; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COHORT STUDIES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PILOT PROJECTS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85047288741     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000446271.28557.e8     Document Type: Article

References (36)

1. Liaw YF. Natural history of chronic hepatitis B virus infection and longterm outcome under treatment. Liver Int 2009; 29(Suppl 1): 100.
2. World Health Organization. Hepatitis B.World Health Organization Fact Sheet 204. 2009.
3. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104.
4. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358.
5. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813.
6. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327.
7. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008; 2: 538.
8. Katz LH, Paul M, Guy DG, et al. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-Analysis. Transpl Infect Dis 2010; 12: 292.
9. Perrillo RP, Wright T, Rakela J, et al. A multicenter United StatesY Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424.
10. Lok AS, Lai CL, Leung N, et al. Long-Term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714.
11. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931.
12. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-Term results. Liver Transpl 2007; 13: 349.
13. Akyildiz M, Karasu Z, Zeytunlu M, et al. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130.
14. Jiao ZY, Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudine combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen. Transplant Proc 2007; 39: 1533.
15. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585.
16. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: A systematic review and Bayesian meta-Analyses. Gastroenterology 2010; 139: 1218.
17. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation. Hepatology 2011; 54: 91.
18. Manns M, Akarca US, Chang TT, et al. Low rates of nucleos(t)ideassociated adverse events in the long-Term experience with entecavir. J Hepatol 2010; 52: S393, Poster 1016.
19. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437.
20. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011.
21. Leung N, Peng CY, Hann HW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009; 49: 72.
22. Chang TT, Lai CL, Kew YS, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422.
23. Tenney DJ, Pokornoski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naBve patients. J Hepatol 2009; 50(suppl 1): S10.
24. Chang TT, Liaw YF, Wu SS, et al. Long-Term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886.
25. Fung J, Cheung C, Chan SC, et al. Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation. Gastroenterology 2011; 141: 1212.
26. Xi ZF, Xia Q, Zhang JJ, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J DigDis 2009; 10: 321.
27. Lo CM, Fung JT, Lau GK, et al. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37: 36.
28. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
29. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
30. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.NEngl J Med 1997; 336: 1855.
31. Xie SB, Zhu JY, Ying Z, et al. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation 2010; 90: 786.
32. Xu X, Tu Z, Wang B, et al. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int 2011; 10: 3231.
33. Lin CC, Chen CL, Concejero A, et al. Active immunization to prevent de novo hepatitis B virus infection in pediatric live donor liver recipients. Am J Transplant 2007; 7: 195.
34. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
35. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823.
36. Dan YY, Wai CT, Yeoh KG, et al. Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost-effectiveness analysis. Liver Transpl 2006; 12: 736.